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Abstract
Aims/hypothesis We sought to establish if stem cells
contained in cord blood cell allografts have the capacity
to differentiate into insulin-expressing beta cells in humans.
Methods We studied pancreases obtained at autopsy from
individuals (n=11) who had prior opposite-sex cord blood
transplants to reconstitute haematopoiesis. Pancreatic tissue
sections were stained first by XY-fluorescence in situ
hybridisation and then insulin immunohistochemistry.
Pancreases obtained at autopsy from participants without
cord blood cell infusions served as controls (n=11).
Results In the men with prior transplant of female cord
blood, there were 3.4±0.3% XX-positive insulin-expressing
islet cells compared with 0.32±0.05% (p<0.01) in male
controls. In women with prior transplant of male cord blood
cells we detected 1.03±0.20% XY insulin-expressing islet
cells compared with 0.03±0.03 in female controls (p<0.001).
Conclusions/interpretation Cord blood stem cells have the
capacity to differentiate into insulin-expressing cells in non-
diabetic humans. It remains to be established whether these
cells have the properties of beta cells.
Keywords Beta cell.Cord blood cell.Diabetes.Stem cell
Abbreviation
FISH fluorescence in situ hybridisation
Introduction
Type 1 diabetes is characterised by a deficit in beta cells,
presumed to be secondary to autoimmune-mediated
destruction [1]. Hyperglycaemia in type 1 diabetes can be
reversed by pancreas transplantation, but this option is
limited by an inadequate supply of organs and the need for
chronic immunosuppression [2]. An alternative strategy is
to replenish beta cells from stem cells, if the stem cells have
the capacity to differentiate into functional beta cells.
Use of allogeneic human embryonic stem cells has
shown some promise although significant obstacles remain,
such as the need for immunosuppression, the risk of
teratoma formation and the need to demonstrate relevant
function of cells that develop [3–5].
Another strategy that has been considered is the use of
bone marrow derived stem cells or their splenic derivatives
as a source of pancreatic beta cells. Some investigators have
reported formation of pancreatic beta cells in mice from
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those findings [8–12]. An alternative explanation for
reversal of diabetes in mice after treatment with bone
marrow derived stem cells is an action of the stem cells to
foster regeneration of islet cells, potentially through
inducing immune protection [13, 14].
Umbilical cord blood stem cells are another source of
stem cells that have been examined for their potential to
generate pancreatic beta cells [15–17]. Human umbilical
cord blood stem cells have been reported to differentiate
into functional pancreatic beta cells in non-obese diabetic
immune-deficient mice, but as yet the issue has not been
addressed in the human pancreas [18].
In the present study we sought to establish if umbilical
cord stem cells transplanted in humans have the capacity
to differentiate into insulin-expressing cells. To accom-
plish this we examined human pancreases obtained at
autopsy from 11 recipients of umbilical cord stem cell
transplants from opposite-sex donors and 11 age- and sex-
matched controls. Survival of the umbilical cord blood
transplant recipients ranged from 11 to 377 days following
transplantation.
Methods
Study design/patients To address the question of whether
insulin-expressing cells can be derived from cord blood
stem cells in human recipients, we sought well-preserved
pancreases obtained at autopsy from recipients of cord
blood cell allografts from opposite-sex donors to provide a
means of tracing the origins of insulin-positive cells. We
identified such pancreases from 18 individuals who had
been transplanted with an opposite-sex umbilical cord
blood graft for haematopoietic rescue after high-dose
chemoradiotherapy for the treatment of a marrow failure
syndrome or lympho-haematopoietic malignancy. The
autopsy study of cord blood recipient pancreas presented
here was approved by the University of Minnesota
(Institutional Review Board [IRB] 0609E93028). Of the
18 potential cases, seven were excluded from the study
owing to inadequate pancreas preservation or sample size.
Eleven individuals (five female, six male) were therefore
included. As controls we obtained well-preserved pan-
creases obtained at autopsy from 11 age- and sex-matched
individuals who did not have prior cord blood transplants,
according to the Mayo Clinic Autopsy Archives. The use of
autopsy tissue from age- and sex-matched controls was
approved by the Mayo Clinic (IRB 1516-03). Cases were
included only if a full autopsy had been performed within
12 h of death and stored pancreatic tissue was of adequate
size and quality. The clinical characteristics of the study
subjects and the control subjects are included in Table 1.
Pancreas processing and immunostaining A portion of
pancreas tail was obtained at autopsy from each cord blood
transplant and control case. After overnight fixation in 10%
formaldehyde, the pancreatic tissue blocks were embedded in
paraffin and 4 μm sections were obtained from the paraffin
blocks. One section from each case was stained with
haematoxylin and eosin and examined (by A. E. Butler) to
exclude autolysis, with none being excluded on this basis.
At least ten tissue sections from each case were first
analysed by fluorescence in situ hybridisation (FISH) to
detect X and Y chromosome-specific signals and subse-
quently for insulin staining as previously described [12]. In
brief, tissue sections were deparaffinised followed by co-
denaturation of the target and probe mix at 73°C for 3 min
prior to hybridisation with Spectrum Green labelled
centromere X/Spectrum Orange labelled centromere dual
colour probes (Abbott-Vysis, Downers Grove, IL, USA). The
slides were hybridised overnight with the probes at 42°C.
After a formamide wash procedure, the slides were rinsed and
stored with PBS for immunostaining. The slides were fixed in
4% paraformaldehyde for 30 min and blocked with TBS-T
(20 mmol/lTris-HCL pH7.4 buffer, 500 mmol/lsaline, 0.05%
Tween-20) with 3% IgG free BSA for 1 h at room
temperature. The slides were then incubated with anti-insulin
primary antibody (Dako, Carpinteria, CA, USA; anti-insulin
dilution 1:400) overnight at 4°C with low-speed rotation. A
second anti-guinea pig conjugated with FITC or CY5 was
used for fluorescent detection of insulin.
To identify macrophages, tissue sections of all transplant
cases and controls were stained first with anti-CD68 (Dako;
dilution 1:200) and subsequently with insulin, as described
above, prior to the FISH procedure. Using this technique,
we could determine if any cells demonstrated co-
localisation of CD68 and insulin, indicating phagocytosis
of a beta cell by a macrophage.
Morphological evaluation and image analysis In the initial
screening for opposite-sex beta cells, all slides were
evaluated independently by two investigators (C. J. Huang
and A. E. Butler) at high-power magnification (×40 or ×63
oil lens) using a Leica DM6000microscope(Leica,Deerfield,
IL, USA) connected to a Macintosh computer loaded with
Openlab software (Improvision, Lexington, MA, USA).
Images were taken at ×40 magnification and stored. Three
tissue sections per case were used for XY-FISH and insulin
immunohistochemistry. A total number of 3,581 insulin-
positive cells were examined from the male cadavers and
2,695 from the female cadavers. Identification of an insulin-
expressing cell as being of opposite-sex origin required both
cytoplasmic insulin staining and the presence of the XX or
XY chromosome complement (both sex chromosomes being
present)asdeterminedbytwoindependentinvestigators(C.J.
Huang and A. E. Butler). Any cells where only a single Yor a
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cells with an aneuploid complement of sex chromosomes
were counted separately as fusion events (see below).
To establish the proportion of cells with an opposite-
sex complement in the exocrine pancreas, a similar
analysis was undertaken in all of the 11 cord blood
transplant samples and three of the control samples.
Images of exocrine pancreas were taken at ×40 magnifi-
cation and analysed independently by the two investiga-
tors. A total of 5,302 exocrine nuclei were analysed in the
six male transplant recipients, and a total of 4,394
exocrine nuclei were analysed from the five female
transplant recipients. A total of 12,115 exocrine nuclei
were evaluated from five control female individuals and a
total of 12,763 exocrine nuclei were evaluated from five
control male individuals.
Whenever an islet cell with cytoplasmic insulin
staining was identified with an opposite-sex comple-
ment of sex chromosomes, or with more than two sex
chromosomes, the nuclear diameters of these cells were
measured as previously described [19]. For comparison,
the nuclear diameters of 30 beta cells were measured
from control individuals. A previous study reported that
beta cells with polyploidy have larger nuclei than
diploid beta cells [20]. Whenever the nuclear diameters
of fusion or grafted insulin-positive cells were measured,
four nearby host insulin-positive cells were also measured
for comparison.
Confocal microscopic analysis In order to further affirm
that insulin-expressing cells with an opposite-sex comple-
ment of sex chromosomes were indeed a consequence of
differentiation from cord stem cells, rather than a conse-
quence of nuclear fusion, pancreases from three of the cord
blood transplant individuals were analysed in further detail
using confocal microscopy. Imaging was performed using a
scanning confocal microscope equipped with argon, green
and red helium-neon lasers (Leica). Images were acquired
by sequential scanning using a ×63 (1.4 numerical aperture)
plan-apochromat oil objective and the appropriate filter
combination. Z sections were captured with a 0.25 μm step
size. The images (1,920×1,080 pixels) were saved as tiff
files for later analysis. A total of 2,485 insulin-expressing
islet cells were analysed by confocal microscopy in these
three cases.
Statistical analysis Data in Table 1 were compared using
the unpaired Student’s t test and presented as means ±
SEM. A value of p<0.05 was taken to be statistically
significant. ANOVA analysis with Fisher’sp o s th o ct e s t
was used where appropriate. Regression analysis was
performed using Statistica, Version 6 (StatSoft, Tulsa, OK,
USA).
Results
Sex chromosome designation in beta cells of control
cases In pancreatic islets from male controls that had not
received a cord blood stem cell transplant we identified
0.32±0.05% (range 0.23–0.47%) beta cells with an XX-
chromosomal complement, presumably reflecting the ad-
mixture of maternal circulating haematogenous stem cells
with fetal circulation at or before birth. The presence of beta
cells with opposite-sex sex chromosomes (XY) was less
common in female controls, being detected in only one of
the five female control individuals, resulting in an overall
frequency of 0.03±0.03%. The one female cadaver in
which beta cells with an opposite-sex complement of sex
chromosomes were identified (with a frequency of 0.17%)
was a 54-year-old woman (case no. 15) who had given birth
to a male child. Thus, XY-positive beta cells in the female
controls are likely to reflect the admixture of residual male
infant-derived haematogenous stem cells at or before birth.
Sex chromosome designation in insulin-expressing cells of
cord blood transfusion recipients The frequency of insulin-
expressing cells with a female complement of sex chromo-
somes was increased in male individuals who had received
a female donor cord blood stem cell transplant compared
with male controls (3.41±0.34 vs 0.32±0.05, p<0.01)
Fig. 1 Islet in male recipient of female umbilical cord blood
transplant. A magnified image (scale bar 5 μm) showing the presence
of an insulin-expressing cell with XX chromosomes (red arrow) in the
nucleus, X chromosomes (red dots by FISH) and cytoplasmic insulin
(yellow by immunofluorescence) from case no. 8. Cells with the
(male) XY sex chromosomes are shown by green arrows (Y
chromosome by FISH green dot). Only cells with both sex
chromosomes present in the nuclear section were attributed a sex
designation as described in the methods. (a) Merged four-colour
image; (b) X chromosome, red; (c) insulin in CY5 (pseudo-colour);
(d) Y chromosome, green; nuclei, DAPI (blue)
Diabetologia (2011) 54:1066–1074 1069(Fig. 1). The case with the highest frequency of opposite-
sex beta cells was 9.8% in a 6-year-old boy with Fanconi
anaemia who had survived for 198 days after receiving a
female umbilical cord blood cell transplant (case no. 6). As
many as ten insulin-expressing cells were present in a
single section in some islets in this case. We also observed
an increased frequency of insulin-expressing cells with a
male complement of sex chromosomes in female individ-
uals who had been transplanted with male cord blood cells
when compared with control females (1.03±0.23 vs 0.03±
0.03%, p<0.001; Figs 2, 3). As is apparent from Table 1,
there was no relationship between the length of life after
cord blood stem cell transplant and the percentage of
insulin-expressing cells with an opposite-sex complement
of sex chromosomes. While there were too few cases
available to establish a recipient effect on the percentage
of opposite-sex insulin-expressing cells, it is of interest
that the two individuals with the highest percentage of
opposite-sex insulin-expressing cells both had Fanconi
anaemia, a condition characterised by a high risk for
diabetes and glucose intolerance during the transplant
process [21]. None of the three individuals with Fanconi
anaemia evaluated here had diabetes or immune cell
infiltration in islets.
All examples of insulin-expressing cells with a comple-
ment of chromosomes reflecting the umbilical cord blood
cell donor were present in pancreatic islets, rather than in the
individual beta cells found scattered in the exocrine pancreas
or in exocrine ducts. This might be because the islet
environment favours umbilical cord blood multi-progenitor
cell recruitment and differentiation, or simply be a statistical
issue with an insufficient number of scattered beta cells to
reveal a relatively low percentage phenomenon.
While the presence of insulin-expressing cells with sex-
mismatchedchromosomesafterumbilicalcordbloodstemcell
transplant could indicate differentiation of cord blood stem
cells into pancreatic beta cells, another explanation that has
been proposed for such a finding is fusion of donor cells with
host cells leading to mosaicism. We next sought to establish if
this was the basis for the increase in opposite-sex insulin-
expressing cells in cord blood stem cell transplant recipients.
Fusion of host beta cells with cord blood cells Using
confocal microscopy to examine the nuclei of insulin-
expressing cells with an apparent mismatch of the sex
chromosomes (see above) we detected examples of nuclear
fusion revealed by two sets of sex chromosomes in the
same nucleus (Fig. 4). Of the 2,485 beta cells from the three
transplant cases that were analysed by confocal microscopy
(Fig. 5), the frequency of opposite-sex insulin-expressing
cells was 1.5%. In addition, 0.76% of insulin-positive cells
were determined to have polyploid (aneuploid) nuclei (three
or more sex chromosomes). Moreover, where cell fusion
had occurred it was readily apparent from the enlarged
nucleus that accompanied the two sets of sex chromosomes
(Fig. 4b). The mean nuclear diameter of beta cells with two
sets of sex chromosomes was ∼40% greater than that of
beta cells with a single set of sex chromosomes (9.5±0.4 vs
6.8±0.3 μm, p<0.001), as previously described [20].
Fig. 3 Mean ± SEM percentage of insulin-positive cells detected with
an opposite-sex complement of sex chromosomes in female controls
(CF), male controls (CM), female recipients of male cord blood
transplants (TxF) and male recipients of female cord blood cell
transplants (TxM). ***p<0. 001, TxF vs CF; **p<0.01 TxM vs CM
Fig. 2 Islet in female recipient of a male umbilical cord blood
transplant. A magnified image (scale bar 5 μm) showing the presence
of insulin-expressing cells with male XY sex chromosomes (green
arrows) in the nucleus as well as host cells with (female) XX sex
chromosomes (red arrows). Cytoplasmic insulin is yellow by
immunofluorescence. All images are from case no. 1. Only cells with
both sex chromosomes present in the nuclear section were attributed a
sex designation as described in the methods. (a–c) Merged four-colour
images; X chromosome, red; Y chromosome, green; insulin in CY5
(pseudo-colour); nuclei, DAPI (blue)
1070 Diabetologia (2011) 54:1066–1074In contrast, the nuclear diameter of insulin-expressing
cells with a single set of opposite-sex sex chromosomes
was no different from that of beta cells with the host
complement of sex chromosomes (7.1±0.4 vs 6.8±0.3 μm,
p=0.63; Fig. 4). We conclude that the majority of insulin-
expressing cells with a complement of sex chromosomes
reflecting that of the cord blood donor rather than the host
were not a consequence of nuclear fusion.
Are insulin-positive cells with opposite-sex sex chromo-
somes macrophages? Another plausible explanation for
insulin-positive cells with a sex chromosome complement
of the opposite sex is the phagocytosis of a host beta cell by
a donor macrophage (derived from the haematogenous
lineage), resulting in a cell with cytoplasmic insulin
immunoreactivity. We did not detect colocalisation of the
macrophage marker CD68 with insulin immunoreactivity in
pancreatic tissue sections in either umbilical cord blood
stem cell recipients or controls (Fig. 6). Indeed, given the
absence of autoimmune type 1 diabetes in any of the
evaluated cases, as expected, the frequency of macrophages
detected in islets was very low, with one exception in a
recipient who had an extensive inflammatory infiltrate in
some regions of the pancreas (case no. 7 and Fig. 6). Even
in this case, we identified no insulin immunoreactivity
coincident with the abundant macrophages. It is therefore
unlikely that the insulin-positive cells with a complement of
sex chromosomes from an opposite-sex cord blood cell
donor represented macrophages after phagocytosis of a beta
cell.
Grafted cells in exocrine tissue area Next, we determined
the frequency of the opposite-sex cells in the exocrine
pancreas of each of the ten transplant recipients (Fig. 7).
The frequency of opposite-sex cells in exocrine pancreas
was 2.20±0.37% (range 1.1–3.1%). A total of 9,763
pancreatic exocrine nuclei were evaluated in the ten cord
blood transfusion recipients (5,369 exocrine nuclei in male
recipients and 4,394 exocrine nuclei in female recipients).
There was no difference between male and female
transfusion recipients in terms of the percentage of
opposite-sex cell engraftment in pancreatic exocrine tissue
(male recipients had 2.14±0.44% opposite-sex cells in
exocrine pancreatic tissue, female recipients had 2.26±
0.37% opposite-sex cells in exocrine pancreatic tissue). A
similar relationship was found between the frequency of
opposite-sex cells in exocrine pancreas and the duration of
survival after cord blood infusion to that previously
observed in humans following opposite-sex bone marrow
transplants [12]. As expected, the frequency of opposite-sex
sex chromosomes in the exocrine cells of the control cases
was lower than in the cord blood stem cell recipients. In
four of the five female controls no opposite-sex comple-
ment of sex chromosomes was detected and in one female
control (case 15, Table 1) two exocrine cells out of 3,608
evaluated had XY sex chromosomes detected, this being
the same individual with a comparably low level of
microchimerism in beta cells, presumably due to bearing
a male infant. In contrast, a low level of microchimerism
was detected in all six of the male controls evaluated,
again comparable with that observed in beta cells, mean
0.32±0.05%.
Discussion
We sought to establish if umbilical cord blood stem cells
include those that have the capacity to differentiate into
pancreatic beta cells in humans. Using sex chromosomes as
Fig. 4 Nuclear enlargement with aneuploidy. a Nuclear diameter is
comparable to adjacent beta cells in an example of an insulin-
expressing cell with a male complement of sex chromosomes (green
arrow) in a female recipient of a male cord blood transplant (case no. 1)
(scale bar 5 μm). b An example of polyploidy (arrowhead) with
nuclear enlargement in a female individual (case no. 1). Adjacent
diploid beta cells have smaller nuclei (arrows) (scale bar 5 μm).
c Mean ± SEM nuclear diameter of diploid host beta cells (host);
insulin-positive cells with sex mismatch sex chromosomes or with
polyploidy (
†p<0.0001)
Diabetologia (2011) 54:1066–1074 1071a surrogate for lineage tracing, the present study reveals that
allograft cord blood stem cell transplants do include cells
with a capacity to differentiate into cells that express insulin
and have the appearance of beta cells in islets of recipients. It
remains to be established whether these cells secrete insulin
in a regulated manner and, if they do, whether they can be
formed in sufficient quantity to be therapeutically useful.
We observed marked variability between individuals in
the percentage of insulin-expressing islet cells with an
opposite-sex (donor) complement of sex chromosomes.
There was no pattern of increased proportion of insulin-
expressing islet cells derived from donor cells in pancreas
examined at autopsy with the time after cord blood
transplant. This may imply that, to the extent that there is
a capacity for cord blood stem cells to form insulin-
expressing islet cells, this occurs early and there is minimal
further contribution from engrafted donor cord blood stem
cells. To make a first estimate of the potential for beta cell
replacement through umbilical cord blood cell transplant, if
umbilical cord blood cell recipients were to accomplish an
increment in beta cells of approximately 2% per treatment,
then 25 treatments would be required to establish a beta cell
mass of ∼50% of normal, a target that approximates the
requirement to establish glucose homeostasis [3, 22, 23]. It
is possible that umbilical cord blood stem cells might be
more frequently recruited to islets in the setting of
inflammation in type 1 diabetes, and perhaps transdiffer-
entiated towards a beta cell phenotype by hyperglycaemia.
However, under these circumstances it is also likely that
Fig. 7 Relationship between percentage of opposite-sex exocrine
cells and survival from cord blood cell transfusion. There was a
gradual increase to steady state at between 50 and 100 days after cord
blood cell transplants. Data obtained from 8,743 nuclei in ten
recipients of cord blood cell transplants
Fig. 6 Macrophages in islets. The macrophage immunomarker CD68
(red) was used with insulin staining (green) and DAPI (blue) to
establish to what extent insulin-expressing cells in the cases studied
here are macrophages following phagocytosis of insulin. As with prior
reports of non-diabetic individuals, macrophages were rarely identi-
fied in islet sections of ten of 11 cases of prior umbilical cord blood
transplants, and in none was insulin immunoreactivity detected in
macrophages. In a and b, images are from two islets from case no. 7 in
which an inflammatory infiltrate was noted in the haematoxylin and
eosin-stained sections, confirmed here to be composed of macro-
phages with no insulin immunoreactivity (scale bar 10 μm)
Fig. 5 Confocal images of an
insulin-expressing cell. Sequen-
tial 0.25 μm z axis images of an
insulin-expressing cell in the
islet of a female recipient of a
male cord blood transplant
(case no. 1) affirming the
presence of just two sex chro-
mosomes (X, red arrow; Y,
green arrow) and assuring that
the nucleus is surrounded by
insulin immunoreactivity (scale
bar 5 μm). X chromosome, red;
Y chromosome, green; insulin in
CY5 (pseudo-colour); nuclei,
DAPI (blue)
1072 Diabetologia (2011) 54:1066–1074any beta cells that arise from cord blood stem cells will be
subject to accelerated loss through autoimmunity [24]. It is of
note there was no discernable increase or preservation of
insulin secretion in child recipients of autologous cord blood
infusions after recent-onset type 1 diabetes mellitus [25].
It is important to consider the validity of the conclusion
that umbilical cord blood stem cells give rise to pancreatic
beta cells. A limitation of the present work is that the
pathology leading to death in the cord blood stem cell
recipients is not the same as that in the control individuals.
Moreover the cord blood stem cell recipients were subject
to marrow ablation prior to transplant. If maternal micro-
chimerism in pancreatic beta cells was to be selectively
enhanced in individuals with haematological malignancies,
Hurler syndrome, Fanconi anaemia and/or bone marrow
ablation, this could give the impression of insulin-
expressing cells derived from cord blood stem cells. On
the other hand, in a prior study of individuals with
haematological malignancies treated with marrow ablation
and subsequent bone marrow transplant from opposite-sex
donors, there was no detectable increase in insulin-
expressing cells by use of the exact same methods used
here [12].
Ideally, to establish the origins of differentiated cells,
lineage tracing is used. However, conventional lineage
studies are not possible in humans. Prior transplantation of
stem cells derived from an opposite-sex donor provides a
unique opportunity to subsequently identify differentiated
cells that have arisen from the stem cells, using the sex
chromosomes as a surrogate for lineage tracing. This
approach, however, is not without pitfalls. One potential
source of error is maternal microchimerism of beta cells
arising from the maternal circulation before, or at the time
of, birth. The frequency of maternal microchimerism (XX
chromosomes) identified in pancreatic beta cells of non-
diabetic male children has previously been reported to be
approximately 0.5% [26, 27] and this could have contrib-
uted to the higher percentage of insulin-positive cells with
an opposite complement of sex chromosomes in male
recipients reported here. Another factor that is likely to
have contributed to this imbalance is that, using the FISH
technique with concurrent insulin staining in the same
sections, the Y chromosome is less readily detected than
the X chromosome. Given the conservative approach that
we adopted to permit the conclusion of an insulin-positive
cell of an opposite-sex origin (both sex chromosomes
must be detected in the same nucleus), it is inevitable that
we have some false negatives, and this will be more
common in female recipients of male umbilical cord blood
transplantation.
Another potential source of error is nuclear fusion
leading to polyploidy [28]. We used two approaches to
minimise this error. To the extent that was practicable, we
employed confocal microscopy to examine the nuclei in
multiple planes to exclude more than two sex chromo-
somes. Second, we compared the nuclear diameter of
insulin-positive cells bearing an opposite-sex complement
of sex chromosomes to that of beta cells surrounding them.
In reality, neither of these approaches is completely
foolproof and so some fraction of the insulin-expressing
cells assigned to be of donor origin may have been due to
unrecognised cell fusion.
An additional potential source of false-positive identifi-
cation of apparent stem cell differentiation into somatic
cells of interest is mismatching of the nucleus with
cytoplasm. This error is a particular concern when insulin
immunostaining to detect beta cells and the FISH technique
to identify sex chromosomes are performed on separate
adjacent tissue sections. To overcome that problem we
previously developed the approach of performing immuno-
histochemistry for insulin on the same tissue section after
the FISH technique [12]. This approach reduces the risk of
false positives but, because some cytoplasm is lost during
the nuclear etching procedure required for the FISH
procedure, it increases false negatives. In this respect, our
method would result in undercounting of opposite-sex cells
rather than overcounting, giving a conservative error.
Finally, it has long been appreciated that host beta cells
that have undergone phagocytosis by a donor macrophage
may be mistakenly identified as beta cells arising from stem
cells, because of the insulin identified in the macrophage
cytoplasm. This is more likely to be a technical challenge
under conditions of islet inflammation, such as in type 1
diabetes. In the present study, as in prior reports of non-
diabetic humans, we rarely identified macrophages in an
islet cross section, the frequency being much lower than
that of the detected insulin-expressing cells with an
opposite-sex complement of sex chromosomes. Moreover
we did not find coincident CD68 and insulin immunoreac-
tivity in the same cell in any sample.
In conclusion, we report that umbilical cord blood cells
do have the capacity to migrate to the pancreatic islet and
differentiate into insulin-expressing cells in humans. This is
in contrast to the absence of insulin-expressing cells with an
opposite-sex complement of sex chromosomes present in
human pancreas after prior bone marrow transplant, when
the same methods were used as here [11]. By implication, it
appears that the stem cells in cord blood may hold more
promise for formation of pancreatic beta cells than those in
bone marrow. However, it remains to be determined
whether insulin-expressing cells that arise from cord blood
cells in humans have the physiological properties of beta
cells. Also, it remains to be determined whether functional
beta cells can thus be generated in sufficient number, and
protected from autoimmunity, to provide useful insulin
secretion in patients with type 1 diabetes.
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